Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M

MEDIFAST INC

2026-Q1 EPS reported -$0.19 revenue$76,044,000

Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.
Active earning coaches dropped 44.9% to 14,000; rev per coach up 19.2% to $5,432.
Gross margin 68.1% vs 72.8% a year ago; operating loss $3.3M vs $1.3M.
Outlook: Q2 rev $60-80M, EPS loss $0.50-$1.00; FY rev $270-300M, EPS loss $1.55-$2.75.
Cash $168.9M, no debt; expects active earning coaches to continue declining in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MEDIFAST INC reported the first quarter ended March 31, 2026 results: revenue $76.0 million, net income $2.1 million, EPS $0.19 per diluted share. Guidance initiated.

Period: the first quarter ended March 31, 2026
Revenue: $76.0 million
Net income: $2.1 million
EPS: $0.19 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

Medifast Announces First Quarter 2026 Financial Results May 4, 2026 BALTIMORE – ( BUSINESS WIRE )-- Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 • Revenue of $76.0 million, with revenue per active earning coach of $5,432 • Independent active earning coaches of 14,000 • Net loss of $2.1 million, or $0.19 per diluted share ("EPS") • Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MEDIFAST INC filing history →

Source: SEC EDGAR

accession 0001628280-26-029812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.